Neowise Biotechnology

Focus: Neowise Biotechnology is a China-based biotech company specializing in TCR-T cell immunotherapies for solid tumors in oncology. The company is in early-stage development with a focused pipeline targeting unmet needs in solid tumor oncology.

Oncology

Profile data last refreshed Yesterday · AI intelligence enriched 2w ago

Open Jobs

About Neowise Biotechnology

AI assessmentNot Hiring

No open roles listed right now. Follow Neowise Biotechnology to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

1/9 — Limited

Company HealthSolid

Pipeline

Early-stage

4 total

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Pipeline & Clinical Trials

NW-301V

Tumor, Solid

Phase 1

Clinical Trials (1)

NCT06484556T Cell Receptor Gene-Engineered T Cell Therapy Targeting KRAS Mutations in the Treatment of Subjects With Advanced Solid Tumor

Phase 1

Help build intelligence for Neowise Biotechnology

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Opportunity to work on cutting-edge TCR-T cell technology, a differentiated approach to solid tumor immunotherapy with significant clinical upside
Early-stage company positioning offers high visibility and direct impact on strategic decisions during critical development phase
China-based location provides access to large patient populations and potentially lower development costs

Watch Out For

Zero current job openings suggest company is not actively hiring, limiting near-term employment opportunities
All programs remain in Phase 1 with no Phase 2 or Phase 3 data, presenting significant clinical and regulatory risk before commercialization

Generated by Claude from Neowise Biotechnology's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

NW-101C

Solid Metastatic Tumor

Phase 1

Clinical Trials (1)

NCT07266298TCR-engineered T Cells (NW-101C) in Patients With Solid Malignant Tumors

Phase 1

NW-301V

Tumor, Solid

Phase 1

Clinical Trials (1)

NCT06478251T Cell Receptor Gene-Engineered T Cell Therapy Targeting KRAS Mutations in the Treatment of Subjects With Advanced Solid Tumor

Phase 1

NW-301V

Tumor, Solid

Phase 1

Clinical Trials (1)

NCT06484790T Cell Receptor Gene-Engineered T Cell Therapy Targeting KRAS Mutations in the Treatment of Subjects With Advanced Solid Tumor

Phase 1

Open Jobs (0)

No open positions listed yet.

Interview Prep Quick Facts

Portfolio: 4 clinical trials

Top TAs: Oncology

Pro Feature

Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.

Upgrade to Pro — $25/mo

Therapeutic Area Focus

Oncology

4 pipeline

Marketed

Pipeline